Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in NSCLC Cachexia
NCT04906746Phase 1Active, not recruiting
- Sponsor
- TuHURA Biosciences, Inc.
- Start
- Feb 2022
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ruxolitinib in cachexia, sponsored by TuHURA Biosciences, Inc. Primary endpoint: Dose-Limiting Toxicity at 3 months. Started Feb 2022; status: active, not recruiting.
02
Drugs
03
Conditions
cachexia
Beyond the preview
Go deeper on NCT04906746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04906746.